Experimental drug tested in people destined for dementia

NCT ID NCT03987295

Completed Disease control Sponsor: Alector Inc. Source: ClinicalTrials.gov ↗

Summary

This study tested an experimental drug called AL001 in people who carry specific genetic mutations that cause frontotemporal dementia, a serious brain disease. The main goal was to check the drug's safety, how the body processes it, and its effects on certain biological markers. It involved 33 participants who received the drug by IV infusion over nearly two years.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Brain Research Center - PPDS

Amsterdam, 1081GN, Netherlands
Erasmus University Medical Center

Rotterdam, 3015 GD, Netherlands
Lawson Health Research Institute, St. Joseph's

London, Ontario, N6A 4V2, Canada
Mayo Clinic

Rochester, Minnesota, 55905, United States
Sunnybrook Health Sciences Centre

Toronto, Ontario, M4N 3M5, Canada
Technical University of Munich

München, 81675, Germany
The Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases UT Health San Antonio

San Antonio, Texas, 78229, United States
UCSF

San Francisco, California, 94158, United States
University College London

London, WC1N 3BG, United Kingdom
University of Brescia

Brescia, 25123, Italy
University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
University of Ulm

Ulm, 89081, Germany

Conditions

Explore the condition pages connected to this study.

FRONTOTEMPORAL DEMENTIA